Page 9 - Ali Tehrani News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Brother of Farideh Moradkhani says the activist is being held in Tehran's notorious Evin Prison

Farideh Moradkhani, an activist who campaigns to abolish the death penalty, spoke out in favour of the ousted pro-Western royal family

Meet The 30 Under 30 Europe In Media And Marketing Class Of 2021 Illustration by Alexander Wells for Forbes Share to Facebook From The Innovators Shaping The Digital Age To The Journalists Breaking New Ground When he started Fanbytes during his second year of university back in 2017, Timothy Armoo wanted to reinvent how brands interact with younger audiences. And in just four years, he’s become an influential leader in the UK’s TikTok scene, helping creators navigate new fame and fortunes while also guiding brands to reach younger audiences on emerging and existing platforms. Armoo, who i...

Press release content from Business Wire. The AP news staff was not involved in its creation. Lifesciences BC’s 6th Annual ACCESS TO INNOVATION Conference Will Generate Important Conversation Between R&D, Academia, Industry and Government February 22, 2021 GMT A compelling and critical conversation will unfold over a two-day period at February 24 – 25, 2021, will host thought leaders from health research & innovation, academia, industry, and government, as well as key individuals in the life science sector from across the country and abroad. The conversation is about therapeutic innovati...

10 Best Biotech Stocks to Invest In According To Billionaire Biotech Hedge Fund Joseph Edelman is one of the most successful biotech hedge fund portfolio managers since he founded Perceptive Advisors in 1999, with the strategy of generating gains by investing in small and mid-cap biotechnology stocks. The assets under management of Edelman’s hedge fund soared from $6 million in 1999 to almost $6.85 billion in the last two decades.  Its flagship fund, Perceptive Life Sciences Fund, specializes in investing money in small- and mid-cap biotech companies. The fund reported losses in 2002, 2008...